ActoGeniX

Ghent, Belgium Founded: 2006 • Age: 20 yrs Acquired By Precigen
Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides.
Annual revenue - Latest available
Total funding $57.2M 4 rounds
Employees - Tracked headcount
Investors 9 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About ActoGeniX

ActoGeniX is a company based in Ghent (Belgium) founded in 2006 was acquired by Precigen in February 2015. ActoGeniX has raised $57.24 million across 4 funding rounds from investors including Gimv, VIB and Precigen. ActoGeniX operates in a competitive market with competitors including Amyris, Inscripta, Pivot Bio, Ginkgo Bioworks and Syngenta, among others.

  • Headquarter Ghent, Belgium
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $57.24 M (USD)

    in 4 rounds

  • Latest Funding Round
    $14.04 M (USD), Series B

    Apr 18, 2013

  • Investors
    Gimv

    & 8 more

  • Employee Count
    Not available
  • Acquired by
    Precigen

    (Feb 13, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ActoGeniX

ActoGeniX has successfully raised a total of $57.24M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14.04 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in ActoGeniX

ActoGeniX has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Gimv, VIB and Precigen.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
Private equity firm
Locked Locked Locked
-
Locked Locked Locked
Premium access

Investor details for ActoGeniX

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ActoGeniX

Investments
Premium access

Investment portfolio details for ActoGeniX

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - ActoGeniX

Premium access

Detailed financials for ActoGeniX

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Actogenix Comparisons

ActoGeniX Primary company
Description
Engineering microbes for in situ expression and secretion of...
Location
Ghent, Belgium
Founded Year
2006
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for ActoGeniX

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ActoGeniX

ActoGeniX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Inscripta, Pivot Bio, Ginkgo Bioworks and Syngenta, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of renewable products for industrial solutions
Locked Locked Locked
Speech recognition solutions are provided by Inscripta for healthcare professionals.
Locked Locked Locked
Nitrogen-fixing microbes for corn crop nutrition are developed and applied.
Locked Locked Locked
Gene editing-based cultured ingredients are provided for agriculture.
Locked Locked Locked
Crop protection solutions and hybrid seeds are provided for farming.
Locked Locked Locked
Provider of integrated suite for advanced genetic design and manufacturing
Premium access

Detailed competitors of ActoGeniX

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Actogenix

Flanders Backs ActoGeniX - PE Hub
Pehub19 years ago
Premium access

Complete news archive for ActoGeniX

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ActoGeniX

ActoGeniX was founded in 2006 and raised its 1st funding round 1 year after it was founded.

ActoGeniX is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.

ActoGeniX is a funded company, having raised a total of $57.24M across 4 funding rounds to date.

ActoGeniX was founded in 2006 in Ghent, Belgium, within the biotechnology sector. Operations center on the TopAct platform, by which food-grade microbes are modified to produce ActoBiotics, orally administered biopharmaceuticals that express cytokines, enzymes, and antibodies locally in the gastrointestinal tract. Clinical products address oral mucositis and inflammatory bowel disease. The company was acquired by Intrexon Corp. in February 2015.

ActoGeniX's top competitors include Syngenta, Synthego and Antheia.

ActoGeniX has 9 investors. Key investors include Gimv, VIB, Precigen, Life Sciences Partners, and Saffelberg Investments.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available